ISOXSUPRINE HYDROCHLORIDE tablet

מדינה: ארצות הברית

שפה: אנגלית

מקור: NLM (National Library of Medicine)

מרכיב פעיל:

isoxsuprine hydrochloride (UNII: V74TEQ36CO) (Isoxsuprine - UNII:R15UI3245N)

זמין מ:

Vedco dba Valdar

מסלול נתינה (של תרופות):

ORAL

סוג מרשם:

PRESCRIPTION DRUG

סממני תרפויטית:

Based on a review of this drug by the National Academy of Sciences-National Research and/or other information, the FDA has classified the indications as follows: - For the relief of symptoms associated with cerebrovascular insufficiency. - In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's disease) and Raynaud's disease. Final classification of the less-than-effective indications requires further investigation. There are no known contraindications to oral use when administered in recommended doses. Isoxsuprine Hydrochloride, USP should not be given immediately postpartum or in the presence of arterial bleeding.

leaflet_short:

Isoxsuprine HCl tablets, USP 20 mg Bottles of 1000 NDC 63549-919-53

מצב אישור:

unapproved drug other

מאפייני מוצר

ISOXSUPRINE HYDROCHLORIDE- ISOXSUPRINE HYDROCHLORIDE TABLET
VEDCO DBA VALDAR
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
ISOXSUPRINE HYDROCHLORIDE TABLETS, USP
RX ONLY
DESCRIPTION
Each tablet taken orally contains Isoxsuprine Hydrochloride, USP with
the following chemical
structure:
C H NO • HCL
p-Hydroxy-α[1-[(methyl-2-phenoxy-ethyl)amino]ethyl]benzyl alcohol
hydrochloride.
QUANTITATIVE INGREDIENT INFORMATION
Each tablet taken orally contains 20mg Isoxsuprine Hydrochloride.
PHARMACOLOGICAL CLASS
Peripheral Vasodilator
INDICATIONS
Based on a review of this drug by the National Academy of
Sciences-National Research and/or other
information, the FDA has classified the indications as follows:
POSSIBLY EFFECTIVE
1. For the relief of symptoms associated with cerebrovascular
insufficiency.
2. In peripheral vascular disease of arteriosclerosis obliterans,
thromboangitis obliterans (Buerger's
disease) and Raynaud's disease.
Final classification of the less-than-effective indications requires
further investigation.
CONTRAINDICATIONS
There are no known contraindications to oral use when administered in
recommended doses.
Isoxsuprine Hydrochloride, USP should not be given immediately
postpartum or in the presence of
arterial bleeding.
18
23
3
PRECAUTIONS
PEDIATRIC USE
Safety and effectiveness in pediatric patients has not been
established.
ADVERSE REACTIONS
On rare occasion oral administration of the drug has been associated
in time with the occurrence of
hypotension, tachycardia, chest pain, nausea, vomiting, dizziness,
abdominal distress, and severe rash. If
rash appears, the drug should be discontinued.
Although available evidence suggests a temporal association of these
reactions with Isoxsuprine
Hydrochloride, a causal relationship can be neither confirmed nor
refuted.
Beta Adrenergic receptor stimulants such as Isoxsuprine Hydrochloride
have been used to inhibit pr